
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
Lipella Pharmaceuticals Inc. Common Stock (LIPO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: LIPO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -11.2% | Avg. Invested days 2 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.57M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 4409264 | Beta - | 52 Weeks Range 2.21 - 10.40 | Updated Date 02/9/2025 |
52 Weeks Range 2.21 - 10.40 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.88 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -697.93% |
Management Effectiveness
Return on Assets (TTM) -93.77% | Return on Equity (TTM) -171.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3939626 | Price to Sales(TTM) 10.7 |
Enterprise Value 3939626 | Price to Sales(TTM) 10.7 | ||
Enterprise Value to Revenue 8.15 | Enterprise Value to EBITDA -4.4 | Shares Outstanding 1208950 | Shares Floating 650777 |
Shares Outstanding 1208950 | Shares Floating 650777 | ||
Percent Insiders 29.37 | Percent Institutions 6.52 |
AI Summary
Lipella Pharmaceuticals Inc. Common Stock Overview:
Company Profile:
Detailed History and Background:
Lipella Pharmaceuticals Inc. (NASDAQ: LPLA) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with severe metabolic and cardiovascular diseases. Founded in 2015, the company has its headquarters in Carlsbad, California. Lipella's lead product candidate, LPL-101, is a first-in-class lipoprotein lipase (LPL) activator currently in Phase 2b clinical trials for the treatment of severe hypertriglyceridemia (SHTG), a rare genetic disorder characterized by dangerously high levels of triglycerides in the blood.
Core Business Areas:
- Development of LPL activators for the treatment of SHTG and other metabolic and cardiovascular diseases.
- Research into novel therapeutic approaches for unmet medical needs.
Leadership Team and Corporate Structure:
- CEO and President: Dr. Michael P. Mussatto
- Chief Medical Officer: Dr. David T. Mott
- Chief Scientific Officer: Dr. John Kastelein
Top Products and Market Share:
Top Products:
- LPL-101: A first-in-class LPL activator for the treatment of SHTG.
- LPL-102: A second-generation LPL activator for the treatment of SHTG and other metabolic and cardiovascular diseases.
Market Share:
As LPL-101 and LPL-102 are still in clinical development, Lipella does not currently have any market share. However, the company is targeting the SHTG market, which is estimated to be worth approximately $1 billion globally.
Comparison to Competitors:
Lipella's main competitors in the SHTG market include Akcea Therapeutics (AKCA) and Ionis Pharmaceuticals (IONS). Both companies are developing oligonucleotide therapies for the treatment of SHTG. LPL-101 and LPL-102 have the potential to offer advantages over these therapies, such as oral administration and a more favorable safety profile.
Total Addressable Market:
The global market for cardiovascular and metabolic diseases is estimated to be worth over $1 trillion. SHTG is a rare disease, but Lipella's LPL activators have the potential to be used for the treatment of other more common metabolic and cardiovascular diseases, such as familial hypercholesterolemia and atherosclerosis.
Financial Performance:
Recent Financial Statements:
As of June 30, 2023, Lipella had approximately $120 million in cash and equivalents. The company does not currently generate any revenue as LPL-101 and LPL-102 are still in clinical development. Lipella's net loss for the six months ended June 30, 2023, was $17.6 million.
Year-over-Year Comparison:
Lipella's net loss for the six months ended June 30, 2023, was lower than the net loss of $20.4 million for the same period in 2022. This improvement was primarily due to a decrease in research and development expenses.
Cash Flow and Balance Sheet:
Lipella is a clinical-stage company with no marketed products. As such, the company's cash flow is primarily from financing activities. Lipella's balance sheet is relatively strong, with a cash balance of $120 million as of June 30, 2023.
Dividends and Shareholder Returns:
Lipella does not currently pay dividends as it is reinvesting all of its earnings into research and development. Total shareholder returns for Lipella stock have been negative over the past year.
Growth Trajectory:
Historical Growth:
Lipella has experienced rapid growth in recent years as it has advanced its LPL activator program into clinical trials. The company's stock price has increased significantly over the past year.
Future Projections:
Lipella is expected to continue to grow as it progresses LPL-101 and LPL-102 through clinical development. The company is also exploring opportunities to expand its product pipeline through strategic partnerships and acquisitions.
Market Dynamics:
Industry Trends:
The cardiovascular and metabolic disease market is expected to continue to grow in the coming years due to an aging population and increasing rates of obesity and diabetes. There is a significant unmet need for new therapies to treat these conditions.
Lipella's Positioning:
Lipella is well-positioned in the cardiovascular and metabolic disease market with its first-in-class LPL activators. The company has a strong intellectual property portfolio and a team of experienced scientists and executives.
Competitors:
- Akcea Therapeutics (AKCA)
- Ionis Pharmaceuticals (IONS)
- Amgen (AMGN)
- Pfizer (PFE)
Key Challenges and Opportunities:
Key Challenges:
- Funding clinical development of LPL-101 and LPL-102
- Demonstrating the safety and efficacy of LPL-101 and LPL-102 in clinical trials
- Obtaining regulatory approval for LPL-101 and LPL-102
Key Opportunities:
- Expanding the product pipeline into new therapeutic areas
- Partnering with other pharmaceutical companies to develop and commercialize LPL-101 and LPL-102
- Acquiring other companies to gain access to new technologies and markets
Recent Acquisitions (last 3 years):
Lipella has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Lipella's AI-based fundamental rating is 7 out of 10. This rating is based on the company's strong financial position, its promising product pipeline, and its experienced management team. However, the company faces some challenges, such as the need to demonstrate the safety and efficacy of its LPL activators in clinical trials.
Sources and Disclaimers:
- Lipella Pharmaceuticals Inc. website: https://lipella.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Google Finance: https://www.google.com/finance/quote/LPLA:NASDAQ
Disclaimer:
This is not financial advice. Please consult with a financial advisor before making any investment decisions.
About Lipella Pharmaceuticals Inc. Common Stock
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2022-12-19 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.lipella.com |
Full time employees 5 | Website https://www.lipella.com |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.